HOME > Drug Approval & Reimbursement in 2023
Drug Approval & Reimbursement in 2023
-
Japan Approves Label Expansions for Rexulti, Rituxan, and More
December 25, 2023
-
Leqembi to Cost 2.98 Million Yen per Year, Re-Pricing Might Be Triggered on Patient Upswing
December 14, 2023
-
Shionogi’s Novel Antibiotic Fetroja Gets Fast-Track Listing for Dec. 20
December 14, 2023
-
Leqembi OK’ed for Listing on Dec. 20; Peak Sales Put at 98.6 Billion Yen
December 13, 2023
-
Japan Approves Meiji’s COVID Vaccine, Daiichi Sankyo’s XBB-Tailored Jab
November 28, 2023
-
Japan Approves Label Expansions for Opdivo, Adcetris, and More
November 27, 2023
-
1st G-Lasta Biosimilar Gets Japan Listing, Stelara Follow-On Not on Roster
November 21, 2023
-
Listing OK’ed for Phesgo, Leqvio, Epkinly, and More; 30 Billion-Plus Yen Peak Sales for 3 Meds
November 16, 2023
-
Wegovy Lands Reimbursement Listing in Japan 8 Months after Approval
November 16, 2023
-
Japan Approves Multiple Firsts, Leqembi, Arexvy, Leqvio, and More
September 26, 2023
-
Japan Approves Eisai/Biogen’s Alzheimer’s Drug Leqembi
September 25, 2023
-
Moderna’s Omicron XBB.1.5 Vaccine Snags Japan Approval
September 12, 2023
-
Japan Approves Pfizer’s Omicron XBB.1.5 Vaccine, Moderna’s Still under Review
September 4, 2023
-
Chuikyo OKs Listing of Litfulo and More; 10 Billion-Plus Yen Peak Sales for Pfizer, Sobi Meds
August 24, 2023
-
Luxturna Priced at 49.6 Million Yen per Vial, Peak Sales Put at 500 Million Yen with 5 Patients
August 24, 2023
-
Japan Approves Enhertu’s NSCLC Use, More Label Expansions
August 24, 2023
-
Japan OKs 1st Homemade COVID Jab, but No Supply Planned; Daiichi to Pursue XBB.1 Update
August 3, 2023
-
Japan Approves Gilead’s HIV Med Sunlenca, Listing Set for Aug. 9
August 2, 2023
-
Japan OKs Oncaspar, Lytgobi, Litfulo, Rinvoq/Keytruda Label Expansions and More
June 27, 2023
-
Japan Approves Novartis’ Gene Therapy Luxturna for Rare Eye Disease
June 27, 2023
ページ
As CEO of Morunda, I had the privilege of interviewing Bill Schuster, Country Manager of Viatris in South Korea. Our conversation delved into the multifaceted nature of leadership in the healthcare industry, exploring challenges, successes, and the power of authenticity.A…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…